Related Experiment Video
Updated: Sep 24, 2025
05:31
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
3.0K
Less invasive aortic valve replacement using the trifecta bioprosthesis.
Alfonso Agnino1,2, Ascanio Graniero1,2, Piersilvio Gerometta1
1Cardiovascular Department, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
Scandinavian Cardiovascular Journal : SCJ
|May 10, 2022
Summary
The Trifecta GT bioprosthesis shows safe and effective results in less invasive aortic valve replacement across multiple surgical approaches. This study confirms excellent hemodynamic performance and no valve-related adverse events during initial follow-up.
Area of Science:
- Cardiovascular Surgery
- Bioprosthetic Devices
- Minimally Invasive Procedures
Background:
- The safety and effectiveness of the Trifecta GT bioprosthesis in minimally invasive aortic valve replacement (AVR) are not well-established.
- Less invasive surgical approaches for AVR are gaining traction, necessitating evaluation of device performance in these techniques.
Purpose of the Study:
- To evaluate the immediate and initial follow-up safety and hemodynamic performance of the Trifecta GT bioprosthesis in less invasive AVR.
- To discuss patient-specific strategies for selecting the optimal surgical approach for AVR.
Main Methods:
- Retrospective review of 133 patients undergoing AVR with the Trifecta GT via three less invasive approaches: upper ministernotomy (UMS), reversed ministernotomy (RMS), and right anterior minithoracotomy (RAMT).
- Data collected included in-hospital outcomes, follow-up events, and hemodynamic performance, specifically assessing patient-prosthesis mismatch (PPM).
- Surgical approach selection was guided by preoperative CT-scan analysis and planned concomitant procedures.
Main Results:
- No operative mortality or valve-related adverse events were observed.
- Two cases (1.5%) of moderate patient-prosthesis mismatch (PPM) and no severe PPM were recorded; no significant perivalvular leaks occurred.
- Excellent hemodynamic performance was maintained at a mean follow-up of 2.5 years, with an average mean gradient of 8 ± 3 mmHg at discharge and no mortality or valve-related events during follow-up.
Conclusions:
- The Trifecta GT bioprosthesis demonstrates reproducible and excellent hemodynamic performance in less invasive AVR, regardless of the specific surgical approach employed.
- Individualized patient selection and surgical approach strategy are crucial for optimal outcomes in less invasive AVR.
- The Trifecta GT bioprosthesis is a safe and effective option for less invasive aortic valve replacement.
